N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. It is also developing Nuvec, an engineered silica nanoparticle for use in intracellular delivery of large nucleic acids, such as pDNA and mRNA; and Single dose Hepatitis B vaccine. The company has a research collaboration with MedImmune to explore the manufacture of a prototype nanomedicine using its Nuvec system. N4 Pharma Plc is based in London, the United Kingdom.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Phone+44-1332-690061
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees5
OptionableNot Optionable
N4 Pharma (LON:N4P) Frequently Asked Questions
What is N4 Pharma's stock symbol?
N4 Pharma trades on the London Stock Exchange (LON) under the ticker symbol "N4P."
Has N4 Pharma been receiving favorable news coverage?
Media headlines about N4P stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. N4 Pharma earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the near term.
Who are some of N4 Pharma's key competitors?
Some companies that are related to N4 Pharma include Allergy Therapeutics (AGY), Bayer (BAYN), Bayer (BAYN), BEXIMCO PHARMAC/S GDR REGS (BXP), Cathay International (CTI), Dechra Pharmaceuticals (DPH), Eco Animal Health Group (EAH), Futura Medical (FUM), Hutchison China MediTech (HCM), OTSUKA HOLDINGS/ADR (OTSKY), Sanofi (SAN), Sareum (SAR), SINR PHAR/PAR VTG FPD 0.01 (SPH) and Vectura Group (VEC).
Who are N4 Pharma's key executives?
N4 Pharma's management team includes the folowing people:
- Mr. Nigel James Theobald, Founder & CEO (Age 55)
- Mr. Paul Titley, Exec. Director
- Dr. Andrew Leishman, Consultant
How do I buy shares of N4 Pharma?
Shares of N4P and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is N4 Pharma's stock price today?
One share of N4P stock can currently be purchased for approximately GBX 8.35.
What is N4 Pharma's official website?
How can I contact N4 Pharma?
N4 Pharma's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061.
MarketBeat Community Rating for N4 Pharma (LON N4P)
MarketBeat's community ratings are surveys of what our community members think about N4 Pharma and other stocks. Vote "Outperform" if you believe N4P will outperform the S&P 500 over the long term. Vote "Underperform" if you believe N4P will underperform the S&P 500 over the long term. You may vote once every thirty days.
